DOM-TOPIRAMATE TABLET
Land: Kanada
Tungumál: enska
Heimild: Health Canada
Vara einkenni
(SPC)
23-08-2019
Sum skjöl fyrir þessa vöru eru ekki tiltæk eins og er, þú getur sent beiðni til þjónustu við viðskiptavini okkar og við munum láta þig vita um leið og við getum fengið þau.
Senda beiðni.
Senda beiðni.
Virkt innihaldsefni:
TOPIRAMATE
Fáanlegur frá:
DOMINION PHARMACAL
ATC númer:
N03AX11
INN (Alþjóðlegt nafn):
TOPIRAMATE
Skammtar:
100MG
Lyfjaform:
TABLET
Samsetning:
TOPIRAMATE 100MG
Stjórnsýsluleið:
ORAL
Einingar í pakka:
100
Gerð lyfseðils:
Prescription
Lækningarsvæði:
MISCELLANEOUS ANTICONVULSANTS
Vörulýsing:
Active ingredient group (AIG) number: 0132938002; AHFS:
Leyfisstaða:
APPROVED
Leyfisdagur:
2005-09-14
Vara einkenni
PRODUCT MONOGRAPH
Pr
Dom-TOPIRAMATE
Topiramate Tablets, House Standard
25 mg, 100 mg and 200 mg
Antiepileptic/Migraine Prophylaxis
DOMINION PHARMACAL
Date of Revision:
6111 Royalmount Ave., Suite 100
August 23, 2019
Montréal, Québec
H4P 2T4
Control No.: 229734
Dom-TOPIRAMATE Product Monograph
Page 2 of 74
Table of Contents
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
................................................................................
3
INDICATIONS AND CLINICAL
USE......................................................................................
3
CONTRAINDICATIONS
...........................................................................................................
4
WARNINGS AND PRECAUTIONS
.........................................................................................
4
ADVERSE REACTIONS
.........................................................................................................
20
DRUG INTERACTIONS
..........................................................................................................
38
DOSAGE AND ADMINISTRATION
......................................................................................
46
OVERDOSAGE
........................................................................................................................
49
ACTION AND CLINICAL PHARMACOLOGY
....................................................................
50
STORAGE AND STABILITY
.................................................................................................
53
DOSAGE FORMS, COMPOSITION AND PACKAGING
..................................................... 53
PART II: SCIENTIFIC INFORMATION
...............................................................................
54
PHARMACEUTICAL INFORMATION
.................................................................................
54
CLINICAL TRIAL
...........................................................................
Lestu allt skjalið
